LIR Life Sciences (N79) 주식 개요LIR 생명과학은 비만 및 대사 장애를 위한 경피 전달 시스템을 개발하는 바이오 제약 회사로 운영되고 있습니다. 자세히 보기N79 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석의미 있는 시가총액이 없습니다(€7M)지난 3개월 동안 주가 변동성이 German 시장과 비교했을 때 매우 높았습니다.cash runway 경력이 1년 미만입니다.수익이 USD$1m 미만입니다(CA$0)모든 위험 점검 보기N79 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value€Current Price€0.23해당 없음내재 할인율Est. Revenue$PastFuture-3m12016201920222025202620282031Revenue CA$1.0Earnings CA$0.1AdvancedSet Fair ValueView all narrativesLIR Life Sciences Corp. 경쟁사TFF PharmaceuticalsSymbol: MUN:0K30Market cap: €9.7mBiofronteraSymbol: XTRA:B8FKMarket cap: €15.0mCantourage GroupSymbol: XTRA:HIGHMarket cap: €77.6mMPH Health CareSymbol: DB:93M1Market cap: €116.5m가격 이력 및 성과LIR Life Sciences 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가CA$0.2352주 최고가CA$1.5852주 최저가CA$0.23베타01개월 변동-44.44%3개월 변동-54.00%1년 변동n/a3년 변동n/a5년 변동n/aIPO 이후 변동-30.39%최근 뉴스 및 업데이트New Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.45m (US$8.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$8.69m).Board Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Kevin May is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.공시 • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.더 많은 업데이트 보기Recent updatesNew Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.45m (US$8.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$8.69m).Board Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Kevin May is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.공시 • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.공시 • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.주주 수익률N79DE PharmaceuticalsDE 시장7D-14.8%-1.5%-3.0%1Yn/a20.8%-0.7%전체 주주 수익률 보기수익률 대 산업: N79의 German Pharmaceuticals 산업 대비 성과를 판단하기에 데이터가 부족합니다.수익률 대 시장: N79의 German 시장 대비 성과를 판단하기에 데이터가 부족합니다.주가 변동성Is N79's price volatile compared to industry and market?N79 volatilityN79 Average Weekly Movement16.3%Pharmaceuticals Industry Average Movement6.0%Market Average Movement5.9%10% most volatile stocks in DE Market13.2%10% least volatile stocks in DE Market2.7%안정적인 주가: N79의 주가는 지난 3개월 동안 German 시장보다 변동성이 컸습니다.시간에 따른 변동성: N79의 주간 변동성(16%)은 지난 1년 동안 안정적이었지만 German 종목 중 상위 75%보다 높습니다.회사 소개설립직원 수CEO웹사이트2024n/aEd Millswww.lirlifesciences.com는 비만 및 대사 장애를 위한 경피 전달 시스템을 개발하는 바이오 제약 회사로 운영되고 있습니다. 이 회사는 2024년에 설립되었으며 캐나다 밴쿠버에 본사를 두고 있습니다.더 보기LIR Life Sciences Corp. 기초 지표 요약LIR Life Sciences의 순이익과 매출은 시가총액과 어떻게 비교됩니까?N79 기초 통계시가총액€7.41m순이익 (TTM)-€1.62m매출 (TTM)n/a0.0x주가매출비율(P/S)-4.4x주가수익비율(P/E)N79는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표N79 손익계산서 (TTM)매출CA$0매출원가CA$10.00k총이익-CA$10.00k기타 비용CA$2.60m순이익-CA$2.61m최근 보고된 실적Jan 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-0.094총이익률0.00%순이익률0.00%부채/자본 비율0%N79의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/12 02:52종가2026/06/12 00:00수익2026/01/31연간 수익2025/04/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스LIR Life Sciences Corp.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.45m (US$8.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$8.69m).
Board Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Kevin May is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.
공시 • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
New Risk • May 31New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.45m (US$8.69m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CA$1.7m free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Revenue is less than US$1m. Market cap is less than US$10m (€7.45m market cap, or US$8.69m).
Board Change • May 20No independent directorsThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, none were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. No independent directors (5 non-independent directors). Director Kevin May is the most experienced director on the board, commencing their role in 2025. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Lack of board continuity. Lack of experienced directors.
공시 • Jan 23LIR Life Sciences Corp. Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic MoleculesLIR Life Sciences Corp. announced the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal penetration of therapeutic macromolecules across a wide molecular size range, spanning approximately 5kDa up to antibody scale (~150kDa). In particular, the study will test whether transdermal agents can help much larger medicines move through skin effectively, which could potentially open the door to developing certain therapies without injections. Working with its scientific partners, LIR has finalized a controlled experimental framework using full thickness porcine skin, which is commonly accepted as one of the most relevant models for human skin permeability. The study is designed to compare transdermal agent-containing formulations with matched controls that contain the same macromolecular payloads without transdermal agents. Penetration depth and distribution will be evaluated using confocal microscopy together with quantitative fluorescence-based measurements collected at predefined time points. These analyses are intended to help determine whether the transdermal agents can meaningfully facilitate the movement of macromolecular therapeutics through the skin to a measurable degree. Completion of the design phase allows LIR to proceed towards formal study execution, which is expected to occur in First Quarter, 2026. The results are expected to inform which categories of larger therapeutic molecules may ultimately be compatible with skin applied, needle free delivery strategies.
공시 • Jan 16LIR Life Sciences Corp. Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation Glp/Gip-Based Obesity TherapiesLIR Life Sciences Corp. announced the launch of a controlled comparative animal study designed to evaluate cell-penetrating peptide (CPP) mediated, needle-free transdermal delivery of second generation GLP/GIP-based obesity therapies. This in vivo study represents an important next step towards advancing LIR's transdermal platform from design-stage planning into functional testing in a small animal model. Working with its scientific collaborators, LIR will assess whether a CPP-enabled, skin-applied formulation of a representative second generation GLP/G IP-based obesity therapy can achieve meaningful biological activity when delivered through the skin. Study animals will receive either a topical CPP formulation or a standard subcutaneous injection, followed by a controlled glucose challenge. Blood glucose levels will be measured over time to compare how effectively each route of administration supports glucose control. The study will use a standard glucose tolerance test, a well-established method in metabolic research and clinical practice. Incretin-based therapies that are working as intended have been shown to help keep the blood sugar curve lower and flatter after the glucose load. If the CPP-enabled transdermal formulation is found to deliver sufficient drug into circulation, LIR expects that animals treated via the skin should show more stable glucose profiles. By focusing on GLP/GIP- based incretin therapies as a class, rather than a single branded product, the study is intended to probe the broader applicability of the CPP-enabled trans Dermal platform. The resulting data are expected to help define where needle-free delivery may match or approach injectable performance and to guide selection of the most promising molecules for further development and potential IND-enabling work. These efforts align with LIR's objective to create patient-friendly, scalable alternatives to injectable incretin therapies for obesity and related metabolic conditions. Needle-free, skin-applied treatments could simplify administration, improve adherence, and reduce treatment burden for patients who might otherwise require frequent injections for long-term weight and glucose management. LIR Life Sciences aims to address the global burden of obesity with practical solutions based on established compounds and proven science.
